These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15508913)

  • 1. Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B.
    Chan EM; Andrade DM; Franceschetti S; Minassian B
    Adv Neurol; 2005; 95():47-57. PubMed ID: 15508913
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in the genetics of progressive myoclonus epilepsy.
    Delgado-Escueta AV; Ganesh S; Yamakawa K
    Am J Med Genet; 2001; 106(2):129-38. PubMed ID: 11579433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the road to tractability: the current biochemical understanding of progressive myoclonus epilepsies.
    Lohi H; Chan EM; Scherer SW; Minassian BA
    Adv Neurol; 2006; 97():399-415. PubMed ID: 16383151
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutations in NHLRC1 cause progressive myoclonus epilepsy.
    Chan EM; Young EJ; Ianzano L; Munteanu I; Zhao X; Christopoulos CC; Avanzini G; Elia M; Ackerley CA; Jovic NJ; Bohlega S; Andermann E; Rouleau GA; Delgado-Escueta AV; Minassian BA; Scherer SW
    Nat Genet; 2003 Oct; 35(2):125-7. PubMed ID: 12958597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuronal survival in epilepsy: to die or not to die?
    Ganesh S; Singh S
    J Biosci; 2005 Dec; 30(5):561-6. PubMed ID: 16388127
    [No Abstract]   [Full Text] [Related]  

  • 6. Generation of a human induced pluripotent stem cell line (UEFi004-A) from a patient with progressive myoclonic epilepsy type 1 (EPM1).
    Singh S; Plotnikova L; Karvonen K; Ryytty S; Hyppönen J; Kälviäinen R; Hämäläinen RH
    Stem Cell Res; 2023 Dec; 73():103248. PubMed ID: 37951142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients.
    Joensuu T; Kuronen M; Alakurtti K; Tegelberg S; Hakala P; Aalto A; Huopaniemi L; Aula N; Michellucci R; Eriksson K; Lehesjoki AE
    Eur J Hum Genet; 2007 Feb; 15(2):185-93. PubMed ID: 17003839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From gene to disease; progressive myoclonus epilepsy of Unverricht-Lundborg and mutations in the cystatin B gene].
    de Haan GJ; Halley DJ; Deelen WH; Lindhout D
    Ned Tijdschr Geneeskd; 2002 May; 146(18):846-8. PubMed ID: 12038222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular background of EPM1-Unverricht-Lundborg disease.
    Joensuu T; Lehesjoki AE; Kopra O
    Epilepsia; 2008 Apr; 49(4):557-63. PubMed ID: 18028412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The autosomal recessively inherited progressive myoclonus epilepsies and their genes.
    Ramachandran N; Girard JM; Turnbull J; Minassian BA
    Epilepsia; 2009 May; 50 Suppl 5():29-36. PubMed ID: 19469843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes.
    Ianzano L; Zhang J; Chan EM; Zhao XC; Lohi H; Scherer SW; Minassian BA
    Hum Mutat; 2005 Oct; 26(4):397. PubMed ID: 16134145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unverricht-Lundborg progressive myoclonus epilepsy in Oman.
    Santoshkumar B; Turnbull J; Minassian BA
    Pediatr Neurol; 2008 Apr; 38(4):252-5. PubMed ID: 18358403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease.
    Shannon P; Pennacchio LA; Houseweart MK; Minassian BA; Myers RM
    J Neuropathol Exp Neurol; 2002 Dec; 61(12):1085-91. PubMed ID: 12484571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1.
    Lehtinen MK; Tegelberg S; Schipper H; Su H; Zukor H; Manninen O; Kopra O; Joensuu T; Hakala P; Bonni A; Lehesjoki AE
    J Neurosci; 2009 May; 29(18):5910-5. PubMed ID: 19420257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and genetics of Unverricht-Lundborg disease.
    Lehesjoki AE
    Adv Neurol; 2002; 89():193-7. PubMed ID: 11968445
    [No Abstract]   [Full Text] [Related]  

  • 16. Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.
    Spuch C; Ortolano S; Navarro C
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):99-107. PubMed ID: 22369717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease.
    Minassian BA
    Adv Neurol; 2002; 89():199-210. PubMed ID: 11968446
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioptically demonstrated Lafora disease without EPM2A mutation: a clinical and neurophysiological study of two sisters.
    Boccella P; Striano P; Zara F; Barbieri F; Sarappa C; Vacca G; de Falco FA; Striano S
    Clin Neurol Neurosurg; 2003 Dec; 106(1):55-9. PubMed ID: 14643920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression.
    Franceschetti S; Sancini G; Buzzi A; Zucchini S; Paradiso B; Magnaghi G; Frassoni C; Chikhladze M; Avanzini G; Simonato M
    Neurobiol Dis; 2007 Mar; 25(3):675-85. PubMed ID: 17188503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three patients with lafora disease: different clinical presentations and a novel mutation.
    Poyrazoğlu HG; Karaca E; Per H; Gümüs H; Onay H; Canpolat M; Canöz Ö; Ozkınay F; Kumandas S
    J Child Neurol; 2015 May; 30(6):777-81. PubMed ID: 25015673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.